News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
EndoCeutics Withdraws IPO
June 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
June 26 (Reuters) - Canada's EndoCeutics Inc. on Tuesday filed with U.S. regulators to withdraw its planned initial public offering, citing current market conditions among other reasons.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
·
1 min read
·
Heather McKenzie
IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
February 4, 2026
·
11 min read
·
Tristan Manalac
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
February 3, 2026
·
1 min read
·
Tristan Manalac
